1Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future [J]. Semin Nephrol, 2000, 20(2): 108 - 125.
2Ponticelli C, Opelz G. Are corticosteroids really necessary in renal transplantation [J] ? Nephrol Dial Transplant, 1995,10(9): 1587 - 1591.
3Fryer JP, Granger DK, Leventhal JR, et al. Steroid-related complications in the cyclosporine era[ J]. Clin Transplant,1994, 8(3 Pt 1):224-229.
4Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation[ J]. Transplantation, 1998, 66(8):1040- 1046.
5Halloran PF. Immunosuppressive agents in clinical trials in transplantation[J]. Am JMed Sci, 1997, 313(5):283 -288.
6Zmonarski SC, Boratynska M, Madziarska K, et al. Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period[ J]. Transplant Proc, 2003, 35(6) :2205 - 2206.
7Behrend M. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation[J]. BioDrugs, 2001, 15(1):37 - 53.
8Hunt SA. New immunosuppressive agents in clinical use:mycophenolate mofetil and tacrolimus [ J ]. Cardiol Rev,2000, 8(3): 180 - 184.
9McDiarmid SV. Mycophenolate mofetil as induction therapy after liver transplantation[J]. Liver Transpl Surg, 1999, 5(4 Suppl 1):S85- S89.
10Modor KG. Mycophenolate mofetil: new application for this immunosuppressant [ J ]. Ann Allergy Asthma Immunol,2003, 90(1):15- 19.
5Anatomical therapeutic chemical (ATC) classification index with Defined Daily Dose (DDDs)[C].WHO collaborating Center for Drug statistics Methodology,Olso,Norway,1997.
6WHO Collaborating Center for Drug Statistics Methodology.Anatomical therapeutic ehemical(ATC) classification index with Defined Daily Dose(DDDs) [C], Olso, Norway, 1997: 2-- 6.
